MX9701765A - Derivado heterociclico y medicina. - Google Patents
Derivado heterociclico y medicina.Info
- Publication number
- MX9701765A MX9701765A MX9701765A MX9701765A MX9701765A MX 9701765 A MX9701765 A MX 9701765A MX 9701765 A MX9701765 A MX 9701765A MX 9701765 A MX9701765 A MX 9701765A MX 9701765 A MX9701765 A MX 9701765A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- represent
- hydrogen
- medicine
- heterocyclic derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Una composicion farmacéutica que comprende un compuesto de la siguiente formula general (I) o su sal: en donde R1 representa arilo o un grupo heteroaromático. R2 representa hidrogeno, alquilo, alquenilo, cicloalquilo, cicloalquilalquilo, hidroxialquilo, haloalquilo, alcoxi, alquiltio, amino, monoalquilamino, dialquilamino, o fenilo. R3 y R4 representan independientemente hidrogeno o alquilo o R3 y R4 tomados junto con el átomo de N adyacente representa un grupo amino cíclico de 5 a 7 elementos. A representa alquileno de C2-10. W representa O, S, o (CH)n (en donde CH puede estar substituido por alquilo; n es un numero entero 0, 1o 2). X, Y, y Z pueden ser los mismos o diferentes y cada uno representa CH (el cual puede estar substituido por alquilo), o N. Sin embargo, siempre que esté excluido el caso en el cual X, Y, y Z representan concurrentemente CH. El compuesto de la invencion tiene una excelente actividad inhibitoria contra la muerte de las neuronas y es util como una droga o fármaco terapéutico para las enfermedades cerebrovasculares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21621494 | 1994-09-09 | ||
PCT/JP1995/001792 WO1996007641A1 (fr) | 1994-09-09 | 1995-09-08 | Derive heterocyclique et medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9701765A true MX9701765A (es) | 1997-06-28 |
Family
ID=16685068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9701765A MX9701765A (es) | 1994-09-09 | 1995-09-08 | Derivado heterociclico y medicina. |
Country Status (19)
Country | Link |
---|---|
US (2) | US5945426A (es) |
EP (1) | EP0781766B1 (es) |
JP (2) | JP3036079B2 (es) |
KR (1) | KR100358245B1 (es) |
CN (1) | CN1118454C (es) |
AT (1) | ATE263154T1 (es) |
BR (1) | BR9508900A (es) |
CA (1) | CA2199518A1 (es) |
DE (1) | DE69532811T2 (es) |
DK (1) | DK0781766T3 (es) |
ES (1) | ES2218552T3 (es) |
FI (1) | FI970967A0 (es) |
HU (1) | HU221855B1 (es) |
MX (1) | MX9701765A (es) |
NO (1) | NO312995B1 (es) |
NZ (1) | NZ292269A (es) |
PT (1) | PT781766E (es) |
RU (1) | RU2128996C1 (es) |
WO (1) | WO1996007641A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1300056B1 (it) * | 1998-04-17 | 2000-04-05 | Boehringer Ingelheim Italia | Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci |
WO2000010571A1 (fr) * | 1998-08-25 | 2000-03-02 | Nippon Shinyaku Co., Ltd. | Antagonistes des canaux calciques |
US20040077709A1 (en) * | 1999-05-31 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
EP1318146B1 (en) * | 2000-09-08 | 2005-02-23 | Nippon Shinyaku Co., Ltd. | Process for producing pyrimidine derivative and intermediate thereof |
IL154418A0 (en) * | 2000-09-19 | 2003-09-17 | Sumitomo Chemical Co | Pyrimidine compounds and their use |
GB0112810D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0112802D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0119477D0 (en) | 2001-08-09 | 2001-10-03 | Glaxo Group Ltd | Pyrimidine derivatives |
US7235560B2 (en) | 2002-08-19 | 2007-06-26 | Glaxo Group Limited | Pyrimidine derivative as selective COX-2 inhibitors |
GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
AU2003222444A1 (en) * | 2003-03-31 | 2004-10-25 | Council Of Scientific And Industrial Research | NEW PYRIMIDINE LINKED PYRROLO(2,1-c)(1,4)BENZODIAZEPINES AS POTENTIAL ANTITUMOUR AGENTS |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
CN102417508A (zh) | 2003-07-14 | 2012-04-18 | 艾尼纳制药公司 | 作为新陈代谢调节剂的稠合芳基和杂芳基衍生物以及预防和治疗与其相关的病症 |
US6966680B2 (en) * | 2003-11-28 | 2005-11-22 | Edward Kratz | Decorative lighting display with changeable shades and bulbs |
DE602005011279D1 (de) * | 2004-06-04 | 2009-01-08 | Arena Pharm Inc | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen |
MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
DOP2006000010A (es) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
CN101263135A (zh) * | 2005-09-16 | 2008-09-10 | 艾尼纳制药公司 | 代谢调节剂和代谢相关病症的治疗 |
TW200811147A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
TW200811140A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
EP1941879A1 (en) * | 2007-01-05 | 2008-07-09 | PAION Deutschland GmbH | Neuroprotective agent for the treatment of neuronal damage |
EP2008653A1 (de) | 2007-06-28 | 2008-12-31 | Charité-Universitätsmedizin Berlin | Serotonerge Verbindungen zur Behandlung neuronaler Krankheiten |
DE102007051090A1 (de) | 2007-06-28 | 2009-01-08 | Charité - Universitätsmedizin Berlin | SSRI zur Behandlung neuronaler Krankheiten |
SG182610A1 (en) | 2010-01-27 | 2012-08-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
KR101871011B1 (ko) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료 |
MX2017008925A (es) | 2015-01-06 | 2017-10-11 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
PT3310760T (pt) | 2015-06-22 | 2022-11-10 | Arena Pharm Inc | Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1 |
JP2020507611A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 原発性胆汁性胆管炎の治療のための化合物および方法 |
EP3953762B1 (en) * | 2019-04-09 | 2022-09-14 | Gentex Corporation | Low dimerizing viologen electrochromic compounds and devices |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3167553A (en) * | 1963-05-08 | 1965-01-26 | Searle & Co | 2-amino-4-ethereal-5-methyl-6-phenylpyrimidines |
BE756127A (fr) * | 1969-09-12 | 1971-03-15 | Hoechst Ag | Ethers heterocycliques et leur preparation |
JPS4921148B1 (es) * | 1970-12-28 | 1974-05-30 | ||
US3937712A (en) * | 1971-09-22 | 1976-02-10 | Boehringer Ingelheim Gmbh | (5-nitro-2-furyl)-pyridines |
BE789099A (fr) * | 1971-09-22 | 1973-03-21 | Boehringer Sohn Ingelheim | Nouveaux derives de la pyridine et procede pour les fabriquer |
US4115575A (en) * | 1973-02-20 | 1978-09-19 | Ciba-Geigy Corporation | 2-(3-Amino-2-hydroxy-propoxy)-pyrazines |
US4698340A (en) * | 1984-07-19 | 1987-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine derivatives, processes for preparation thereof and composition containing the same |
US4727073A (en) * | 1984-10-01 | 1988-02-23 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine derivatives and composition of the same |
CA2090027A1 (en) * | 1990-08-31 | 1992-03-01 | Shoichi Chokai | Pyrimidine derivatives and drugs |
US5294612A (en) * | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
IL117659A (en) * | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
-
1995
- 1995-09-08 WO PCT/JP1995/001792 patent/WO1996007641A1/ja active IP Right Grant
- 1995-09-08 AT AT95930725T patent/ATE263154T1/de not_active IP Right Cessation
- 1995-09-08 BR BR9508900A patent/BR9508900A/pt not_active IP Right Cessation
- 1995-09-08 MX MX9701765A patent/MX9701765A/es not_active IP Right Cessation
- 1995-09-08 DK DK95930725T patent/DK0781766T3/da active
- 1995-09-08 US US08/809,004 patent/US5945426A/en not_active Expired - Fee Related
- 1995-09-08 ES ES95930725T patent/ES2218552T3/es not_active Expired - Lifetime
- 1995-09-08 DE DE69532811T patent/DE69532811T2/de not_active Expired - Fee Related
- 1995-09-08 HU HU9800853A patent/HU221855B1/hu not_active IP Right Cessation
- 1995-09-08 PT PT95930725T patent/PT781766E/pt unknown
- 1995-09-08 KR KR1019970701494A patent/KR100358245B1/ko not_active IP Right Cessation
- 1995-09-08 CN CN95195014A patent/CN1118454C/zh not_active Expired - Fee Related
- 1995-09-08 JP JP8509379A patent/JP3036079B2/ja not_active Expired - Fee Related
- 1995-09-08 CA CA002199518A patent/CA2199518A1/en not_active Abandoned
- 1995-09-08 RU RU97105769A patent/RU2128996C1/ru not_active IP Right Cessation
- 1995-09-08 NZ NZ292269A patent/NZ292269A/en unknown
- 1995-09-08 EP EP95930725A patent/EP0781766B1/en not_active Expired - Lifetime
-
1997
- 1997-03-07 FI FI970967A patent/FI970967A0/fi unknown
- 1997-03-07 NO NO19971050A patent/NO312995B1/no unknown
-
1999
- 1999-06-16 US US09/334,253 patent/US6191149B1/en not_active Expired - Fee Related
- 1999-11-26 JP JP33560399A patent/JP3312616B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69532811T2 (de) | 2005-03-17 |
PT781766E (pt) | 2004-07-30 |
AU701395B2 (en) | 1999-01-28 |
FI970967A (fi) | 1997-03-07 |
RU2128996C1 (ru) | 1999-04-20 |
KR970705545A (ko) | 1997-10-09 |
NZ292269A (en) | 1998-09-24 |
US6191149B1 (en) | 2001-02-20 |
CN1157609A (zh) | 1997-08-20 |
EP0781766A4 (en) | 1998-01-14 |
ATE263154T1 (de) | 2004-04-15 |
HU221855B1 (hu) | 2003-02-28 |
BR9508900A (pt) | 1997-12-30 |
FI970967A0 (fi) | 1997-03-07 |
AU3399695A (en) | 1996-03-27 |
NO312995B1 (no) | 2002-07-29 |
EP0781766B1 (en) | 2004-03-31 |
DK0781766T3 (da) | 2004-07-26 |
CA2199518A1 (en) | 1996-03-14 |
ES2218552T3 (es) | 2004-11-16 |
EP0781766A1 (en) | 1997-07-02 |
WO1996007641A1 (fr) | 1996-03-14 |
NO971050L (no) | 1997-05-09 |
DE69532811D1 (de) | 2004-05-06 |
JP3312616B2 (ja) | 2002-08-12 |
HUT77779A (hu) | 1998-08-28 |
JP3036079B2 (ja) | 2000-04-24 |
NO971050D0 (no) | 1997-03-07 |
CN1118454C (zh) | 2003-08-20 |
KR100358245B1 (ko) | 2003-11-28 |
US5945426A (en) | 1999-08-31 |
JP2000136184A (ja) | 2000-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9701765A (es) | Derivado heterociclico y medicina. | |
GB0009532D0 (en) | Chemical compounds | |
MY104652A (en) | A spiro compound | |
ES2124545T3 (es) | Azolidindionas como agentes antihiperglucemicos. | |
HUT57710A (en) | Process for producing amidine and guanidine derivatives and pharmaceutical compositions comprising such active ingredient | |
IL119321A0 (en) | Substituted milbemycin 5-oxime derivatives and pesticidal compositions containing the same | |
EP0775487A4 (en) | TRIAZINE DERIVATIVE AND MEDICINE | |
EP0567090A3 (es) | ||
ATE231124T1 (de) | Azetidinonderivate zur behandlung von hcmv entzündungen | |
LV11832A (lv) | O-acil-4-fenilcikloheksanoli to salis zalu lidzekli kas satur minetas vielas un to pielietojums | |
ATE215075T1 (de) | Hydroxylamin-derivate mit anti-ischämischer wirkung und pharmazeutische zusammensetzungen diese enthaltend | |
ATE66475T1 (de) | Aromatische thioaether. | |
DE3770481D1 (de) | Verwendung von imidazochinazolinen zur behandlung und verhinderung von nephritis. | |
DE69214180D1 (de) | Verwendung von Bis-(p-Hydroxyphenylthio)methanderivaten zur Hemmung der fortschreitenden Entwicklung von insulinabhängingem Diabetes mellitus | |
TH8125A (th) | สารกำจัดเชื้อราประเภทอาคริลเลท | |
TH13532EX (th) | อนุพันธ์ พิริดิลอกซิซึ่งต่อต้านแผลเปื่อย การเตรียมและการใช้สารเหล่านั้น | |
TH13532A (th) | อนุพันธ์ พิริดิลอกซิซึ่งต่อต้านแผลเปื่อย การเตรียมและการใช้สารเหล่านั้น | |
TH8125EX (th) | สารกำจัดเชื้อราประเภทอาคริลเลท | |
TW200504023A (en) | Substituted pyri(mi)dine(thio)carboxamides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |